CD274 and neoplasm: SAR405 has been reported to inhibit the tumor growth or proliferation of CRC [105], melanoma [105], breast cancer [107], and head and neck SCC [110] when used alone and to synergize with cisplatin [110,128], lapatinib [107], BYL719 [107], everolimus [129], and anti-PD-L1/PD-1 immunotherapy [105].